Progressive brain disorder causing memory loss and cognitive decline; currently linked to new trials, therapies, and risk factors in public debate.
A two-year Latin American trial has shown that older adults at risk of dementia who followed a structured lifestyle program—combining supervised exercise, brain-healthy diet guidance, cognitive training, and social activity—outperformed a control group in cognition, memory, and processing speed.
A French charity has held its third raffle offering a Picasso painting for €100. The gouache work from 1941 has been won by a Parisian software salesman, with proceeds supporting Alzheimer’s research. The event has raised over €10 million across three editions, emphasizing art’s role in philanthropy.
Recent studies have shown significant advances in gene therapy for hearing loss and eye conditions, as well as promising research on reversing brain inflammation linked to aging. Meanwhile, new evidence questions the effectiveness of Alzheimer’s drugs, highlighting ongoing challenges in neurodegenerative treatments. Today's date is Mon, 27 Apr 2026 11:37:39 +0100.
A UK-led study shows a finger-prick blood test combined with online cognitive testing could triage dementia risk from home, while another tool using interpretable AI predicts 10-year obesity-related health risks to guide NHS interventions. Separately, an AI-assisted triage study in emergency medicine suggests AI may outperform humans in rapid decision-making, signaling a shift in clinical workflows.
Independent coverage notes Labour leader Burnham argues for stability to unlock people’s potential, echoing Lord Kinnock’s praise of education and social mobility; Guardian reports Danny Glover reveals Alzheimer’s diagnosis and outlook; Independent covers ADHD revelation by Frankie Bridge and Amanda Welch; Nestor reveals cancer treatment update; Glover’s career and humanitarian work highlighted.
Biogen’s tau-targeting drug diranersen has shown potential in reducing tau levels and slowing cognitive decline in a small subset of a 400-person study, prompting plans for a larger trial. The results, presented at the Alzheimer’s Association International Conference in London, are cautiously optimistic but require confirmation in bigger studies.